Fresh analysis reveals that individuals who come off popular GLP-1 drugs like semaglutide or tirzepatide tend to recover lost weight at a significantly accelerated pace than those who halt conventional diet and exercise programs.
Findings released in a leading medical journal shows that while overweight people frequently drop about a fifth of their body weight while undergoing treatment, the weight returns at an average rate of nearly a kilo each month after stopping.
"Users buying these medications need to be aware of the potential of rapid weight regain when the treatment concludes," warns researcher Dr. Susan Jebb.
Such speed of recovery implies a reversion to starting mass within about 18 months.
Analyzing Approaches
The analysis, which reviewed 37 of studies involving thousands of participants, compared the results of GLP-1 agonists with older methods.
The team emphasize that individuals who shed pounds through diet and exercise typically have a less rapid weight regain—approximately 100 grams monthly—post-intervention.
The Reason for the Rapid Regain
Doctors suggest the mechanism of the injections is key to understanding the amplified rebound.
These medications mimic a natural hormone called GLP-1, which moderates feelings of fullness.
"Sustained high doses of the hormone levels several times higher than the body's typical production might result in the body to generate a reduced amount of its endogenous GLP-1, and could lessen responsiveness to its actions," noted Dr. Adam Collins, a nutrition specialist.
"Discontinuation of this medication leads to hunger is uncontrolled, making binge eating much more probable."
An Ongoing Issue?
Health authorities advise the injections for individuals with obesity-related medical conditions, alongside recommended diet and exercise modifications.
Many experts argue that, given the high risk of weight regain, the treatment might need to be long-term.
This perspective is supported by drug manufacturers, who note that the findings "highlight the chronic nature of obesity," similar to managing diseases like high blood pressure.
User Testimonies
People who have discontinued the medication describe a powerful return of appetite.
"It felt as if a switch that goes on and I was suddenly ravenous," recalled an individual.
This difficulty is compounded if patients have not developed sustainable lifestyle or habit modifications during therapy.
Growing Adoption
Survey data indicate that a significant number of people in the UK have used these injections in the past year, with desire being substantial.
- Use is higher among women compared to men.
- The middle-aged demographic shows the highest level of interest.
- Many access the drugs through private prescriptions rather than public health services.
Ultimately, researchers caution that while the jabs are effective agents for shedding pounds, they are not a permanent cure and lasting health benefits likely depends on integrated behavioural changes.
